NLS Pharmaceutics AG Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
6NLS Pharmaceutics's Business Model
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
About NLS Pharmaceutics
Website: https://nlspharma.com
CEO (Chief Executive Officer): Mr. Alexander Zwyer M.B.A.
IPO date: 2021-01-29
Contact
Country: CH
Address: The Circle 6
City: Zurich
State: None
Phone: 41 44 512 21 50
Zip Code: 8058
Other
CIK: 0001783036
ISIN: CH0523961370
CUSIP: H57830103
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
